HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Consumer Health Has Digital And Natural Drivers For ‘Above Market’ Growth

Executive Summary

OTC drug sales grew worldwide 4.4% on an operational basis to $4.34bn, with US segment driving increase. US OTC sales jumped 7.8% to reach $1.85bn and international sales grew 2.1% to $2.48bn. J&J consumer segment got a lift from mid-year addition of Zarbees.

You may also be interested in...



Balancing Beauty Lineup With International And Regional Brands Factors In J&J Consumer Growth

While J&J benefits from “underlying strength” of its large skin care brands, it targets “regular additions of local, smaller brands,’ says global consumer business head Thibaut Mongon. Portfolio balance of international and localized brands helps it weather economic uncertainty during the COVID-19 pandemic.

J&J International Baby, Beauty Lines Could Lead Trimming 10% Of Consumer Portfolio

J&J plans to cut 10% of its consumer health portfolio, with most divestitures in the baby and beauty care segments outside the US. It plans to focus on growing “stronghold” categories of skin health and self care, including Aveeno and Tylenol.

J&J Expects Persistent Pricing Pressure Into 2019

CEO Alex Gorsky highlighted growing public concern over US drug costs during J&J's Q4 earnings call, pressing for more transparency and value-based health care. The company's net drug prices declined more than 6% in 2018, he added.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel